Table 8.
miRNAs associated with positive outcome | ||||||
---|---|---|---|---|---|---|
miRNA | Case cohort | Validation cohort | Reference | |||
Detection | Cells of origin | Number of samples | Technique | Number of samples | ||
let-7b | LNA-ISH | Early invasive BC | 1,432 | qRT-PCR | 40 | [97] |
LNA-ISH | Heterogeneous BC | 80 | NR | NR | [101] | |
miR-205 | LNA-ISH | Ductal BC | 1,475 | qRT-PCR | 40 | [97] |
qRT-PCR | Heterogeneous BC | 84 | NR | NR | [102] | |
miR-375 | Solexa deep sequencing | Stage II-III BC | 42 | qRT-PCR | 26 | [57] |
miR-30a | miRNA microarray | IDC | 221 | NR | NR | [104] |
qRT-PCR | Heterogeneous BC | 96 | NR | NR | [108] | |
miR-342-5p | miRNA microarray | Heterogeneous BC | 101 | miRNA microarray | 1,302 | [109] |
miR-497 | qRT-PCR | Heterogeneous BC | 128 | NR | NR | [111] |
qRT-PCR | IDC | 48 | NR | NR | [110] |
BC, breast cancer; IDC, invasive ductal carcinoma; LNA-ISH, Locked Nucleic Acid-in situ hybridization; miRNA, microRNA; NR, not reported; qRT-PCR, quantitative real-time polymerase chain reaction.